Quick Takeaways
- GOLDMAN SACHS GROUP INC filed SCHEDULE 13G/A for FATE THERAPEUTICS, INC. Common Stock, par value $0.001 per share (FATE).
- Disclosed ownership: 2%.
- Date of event: 30 Jun 2025.
GOLDMAN SACHS GROUP INC - 30 Jun 2025 SCHEDULE 13G/A Report for FATE THERAPEUTICS, INC. Common Stock, par value $0.001 per share (FATE)
- Filing Manager
- GOLDMAN SACHS GROUP INC
- Reporting Manager
- THE GOLDMAN SACHS GROUP, INC.
- Symbol
- FATE
- Shares outstanding
- 113,701,004 shares
- Disclosed Ownership
- 2,274,020 shares
- Ownership
- 2%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Aug 2025, 11:30:17 UTC
- Date of event
- 30 Jun 2025
- Previous filing
- 09 May 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"GOLDMAN SACHS GROUP INC disclosed 2% ownership in FATE THERAPEUTICS, INC. Common Stock, par value $0.001 per share (FATE) on 30 Jun 2025."
What Changed
- Previous schedule filing date: 09 May 2025.
- Current filing was accepted on 14 Aug 2025, 11:30.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| THE GOLDMAN SACHS GROUP, INC. | 2% | 2,274,020 | 0 | 2,273,623 | Name: Veronica Mupazviriwo | Attorney-in-fact | |
| GOLDMAN SACHS & CO. LLC | 2% | 2,274,020 | 0 | 2,273,623 | Name: Veronica Mupazviriwo | Attorney-in-fact |